1
|
Albertini B, Bertoni S, Nucci G, Botti G, Abrami M, Sangiorgi S, Beggiato S, Prata C, Ferraro L, Grassi M, Passerini N, Perissutti B, Dalpiaz A. Supramolecular eutectogel as new oral paediatric delivery system to enhance benznidazole bioavailability. Int J Pharm 2024; 661:124417. [PMID: 38964489 DOI: 10.1016/j.ijpharm.2024.124417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Revised: 06/28/2024] [Accepted: 07/01/2024] [Indexed: 07/06/2024]
Abstract
Benznidazole (BNZ) serves as the primary drug for treating Chagas Disease and is listed in the WHO Model List of Essential Medicines for Children. Herein, a new child-friendly oral BNZ delivery platform is developed in the form of supramolecular eutectogels (EGs). EGs address BNZ's poor oral bioavailability and provide a flexible twice-daily dose in stick-pack format. This green and sustainable formulation strategy relies on the gelation of drug-loaded Natural Deep Eutectic Solvents (NaDES) with xanthan gum (XG) and water. Specifically, choline chloride-based NaDES form stable and biocompatible 5 mg/mL BNZ-loaded EGs. Rheological and Low-field NMR investigations indicate that EGs are viscoelastic materials comprised of two co-existing regions in the XG network generated by different crosslink distributions between the biopolymer, NaDES and water. Remarkably, the shear modulus and relaxation spectrum of EGs remain unaffected by temperature variations. Upon dilution with simulated gastrointestinal fluids, EGs results in BNZ supersaturation, serving as the primary driving force for its absorption. Interestingly, after oral administration of EGs to rats, drug bioavailability increases by 2.6-fold, with a similar increase detected in their cerebrospinal fluid. The noteworthy correlation between in vivo results and in vitro release profiles confirms the efficacy of EGs in enhancing both peripheral and central BNZ oral bioavailability.
Collapse
Affiliation(s)
- Beatrice Albertini
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy.
| | - Serena Bertoni
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy
| | - Giorgia Nucci
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy
| | - Giada Botti
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Fossato di Mortara 19, I-44121 Ferrara, Italy
| | - Michela Abrami
- Department of Engineering and Architecture, University of Trieste, Via Alfonso Valerio, 6/1, I-34127 Trieste, Italy
| | - Stefano Sangiorgi
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy
| | - Sarah Beggiato
- Department of Life Sciences and Biotechnology, University of Ferrara and LTTA Center, Via L. Borsari 46, I-44121 Ferrara, Italy
| | - Cecilia Prata
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy
| | - Luca Ferraro
- Department of Life Sciences and Biotechnology, University of Ferrara and LTTA Center, Via L. Borsari 46, I-44121 Ferrara, Italy
| | - Mario Grassi
- Department of Engineering and Architecture, University of Trieste, Via Alfonso Valerio, 6/1, I-34127 Trieste, Italy
| | - Nadia Passerini
- Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, I-40127 Bologna, Italy
| | - Beatrice Perissutti
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Piazzale Europa 1, I-34127 Trieste, Italy
| | - Alessandro Dalpiaz
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Fossato di Mortara 19, I-44121 Ferrara, Italy
| |
Collapse
|
2
|
Magi MS, Lopez-Vidal L, García MC, Stempin CC, Marin C, Maletto B, Palma SD, Real JP, Jimenez-Kairuz AF. Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease. Ther Deliv 2024:1-18. [PMID: 39101355 DOI: 10.1080/20415990.2024.2380244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 07/11/2024] [Indexed: 08/06/2024] Open
Abstract
Aim: Benznidazole (BNZ), a class-II drug, is the primary treatment for Chagas disease, but its low aqueous solubility presents challenges in formulation and efficacy. Nanosuspensions (NS) could potentially address these issues. Methods: BNZ-NS were prepared using a simple, organic solvents-free nano-milling approach. Physicochemical characterizations were conducted on both NS and lyophilized solid-state BNZ-nanocrystals (NC). Results: BNZ-NS exhibited particle size <500 nm, an acceptable polydispersity index (0.23), high Z-potential, and physical stability for at least 90 days. BNZ-NC showed tenfold higher solubility than pure BNZ. Dissolution assays revealed rapid BNZ-NS dissolution. BNZ-NC demonstrated biocompatibility on an eukaryotic cell and enhanced BNZ efficacy against trypomastigotes of Trypanosoma cruzi. Conclusion: BNZ-NS offers a promising alternative, overcoming limitations associated with BNZ for optimized pharmacotherapy.
Collapse
Affiliation(s)
- María Sol Magi
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Lucía Lopez-Vidal
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Mónica Cristina García
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Cinthia Carolina Stempin
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Constanza Marin
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Belkys Maletto
- Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Santiago Daniel Palma
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Juan Pablo Real
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| | - Alvaro Federico Jimenez-Kairuz
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET/UNC, 1-4 Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, X5000HUA, Argentina
| |
Collapse
|
3
|
Magi MS, Lopez-Vidal L, Rega P, Ibarra M, Palma SD, Jimenez Kairuz A, Real JP. 3D printed benznidazole tablets based on an interpolyelectrolyte complex by melting solidification printing process (MESO-PP): An innovative strategy for personalized treatment of Chagas disease. Int J Pharm 2024; 662:124476. [PMID: 39029635 DOI: 10.1016/j.ijpharm.2024.124476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 07/12/2024] [Accepted: 07/13/2024] [Indexed: 07/21/2024]
Abstract
3D printing technology is revolutionizing pharmaceuticals, offering tailored solutions for solid dosage forms. This innovation is particularly significant for conditions like Chagas disease, which require weight-dependent treatments. In this work, a formulation of benznidazole (BNZ), the primary treatment for this infection, was developed to be utilized with the Melting Solidification Printing Process (MESO-PP) 3D printing technique. Considering the limited aqueous solubility of BNZ, an interpolyelectrolyte complex (IPEC), composed of chitosan and pectin, was integrated to improve its dissolution profile. The formulations, also called inks in this context, with and without IPEC were integrally characterized and compared. The printing process was studied, the release of BNZ from 3D-prints (3DP) was exhaustively analyzed and a physiologically based pharmacokinetic model (PKPB) was developed to forecast their pharmacokinetic performance. 3DP were successfully achieved loading 25, 50 and 100 mg of BNZ. The presence of the IPEC in the ink caused a decrease in the crystalline domain of BNZ and facilitated the printing process, reaching a print success rate of 83.3 %. Interestingly, 3DP-IPEC showed accelerated release dissolution profiles, releasing over 85 % of BNZ in 90 min, while 3DP took up to 48 h for doses above 25 mg. The PBPK model demonstrated that 3DP-IPEC tablets would present high bioavailability (0.92), higher than 3DP (0.36) and similar to the commercial product. This breakthrough holds immense potential for improving treatment outcomes for neglected diseases.
Collapse
Affiliation(s)
- María Sol Magi
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Ciencias Farmacéuticas, Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA, Córdoba, Argentina
| | - Lucía Lopez-Vidal
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Ciencias Farmacéuticas, Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA, Córdoba, Argentina
| | - Patricia Rega
- Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos (CEBIOBE), Departamento de Ciencias Farmacéuticas, Facultad de Química, Universidad de la República, Montevideo, Uruguay
| | - Manuel Ibarra
- Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos (CEBIOBE), Departamento de Ciencias Farmacéuticas, Facultad de Química, Universidad de la República, Montevideo, Uruguay
| | - Santiago Daniel Palma
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Ciencias Farmacéuticas, Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA, Córdoba, Argentina
| | - Alvaro Jimenez Kairuz
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Ciencias Farmacéuticas, Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA, Córdoba, Argentina.
| | - Juan Pablo Real
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Ciencias Farmacéuticas, Córdoba, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA, Córdoba, Argentina.
| |
Collapse
|
4
|
Baldiviezo LV, Nieva LB, Pedrini N, Cardozo RM. Microencapsulation of a Native Strain of the Entomopathogenic Fungus Beauveria bassiana and Bioinsecticide Activity against Pyrethroid-Resistant Triatoma infestans to Vector Control of Chagas Disease in the Argentine Gran Chaco Region. Trop Med Infect Dis 2023; 8:tropicalmed8050245. [PMID: 37235293 DOI: 10.3390/tropicalmed8050245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 04/20/2023] [Accepted: 04/22/2023] [Indexed: 05/28/2023] Open
Abstract
The blood-sucking bug Triatoma infestans is the main Chagas disease vector in the Southern Cone of Latin America. Populations resistant to pyrethroid insecticides have been detected in the early 2000s and then expanded to the endemic area of northern Salta province, Argentina. In this context, the entomopathogenic fungus Beauveria bassiana has been shown to be pathogenic to pyrethroid-resistant T. infestans. In this study, both the bioinsecticidal activity and the residual effect of an alginate-based microencapsulation of a native strain of B. bassiana (Bb-C001) were tested under semi-field conditions against pyrethroid-resistant T. infestans nymphs. Fungal microencapsulated formulation caused higher nymph mortality than the unmicroencapsulated fungus and contributed to maintaining the conidial viability throughout the period evaluated under the tested conditions. These results suggest that alginate microencapsulation is an effective, simple, low-cost method that could be incorporated into the formulation of a bioinsecticide as a strategy to reduce the vector transmission of Chagas disease.
Collapse
Affiliation(s)
- Linda Vanesa Baldiviezo
- Facultad de Ciencias Naturales, Universidad Nacional de Salta, Av. Bolivia 5150, Salta 4400, Argentina
- Ministerio de Salud Pública de la Provincia de Salta (MSPS), Salta 4400, Argentina
| | - Lucía Beatriz Nieva
- Facultad de Ciencias Naturales, Universidad Nacional de Salta, Av. Bolivia 5150, Salta 4400, Argentina
| | - Nicolás Pedrini
- Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CCT La Plata Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata (UNLP), Calles 60 y 120, La Plata 1900, Argentina
| | - Rubén Marino Cardozo
- Facultad de Ciencias Naturales, Universidad Nacional de Salta, Av. Bolivia 5150, Salta 4400, Argentina
- Ministerio de Salud Pública de la Provincia de Salta (MSPS), Salta 4400, Argentina
| |
Collapse
|
5
|
Development of melatonin-loaded, human-serum-albumin nanoparticles formulations using different methods of preparation for ophthalmic administration. Int J Pharm 2022; 628:122308. [DOI: 10.1016/j.ijpharm.2022.122308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 10/11/2022] [Accepted: 10/12/2022] [Indexed: 10/31/2022]
|
6
|
Dain IA, Zolotov SA, Demina NB, Zolotova AS, Buzanov GA, Retivov VM, Ponomaryov YS. Complex dispersions of poloxamers and mesoporous carriers with ibrutinib. OPENNANO 2022. [DOI: 10.1016/j.onano.2022.100073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Current Trends on Solid Dispersions: Past, Present, and Future. Adv Pharmacol Pharm Sci 2022; 2022:5916013. [PMID: 36317015 PMCID: PMC9617737 DOI: 10.1155/2022/5916013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/10/2022] [Accepted: 09/21/2022] [Indexed: 11/07/2022] Open
Abstract
Solid dispersions have achieved significant interest as an effective means of enhancing the dissolution rate and thus the bioavailability of a range of weakly water-soluble drugs. Solid dispersions of weakly water-soluble drugs with water-soluble carriers have lowered the frequency of these problems and improved dissolution. Solid dispersion is a solubilization technology emphasizing mainly on, drug-polymer two-component systems in which drug dispersion and its stabilization is the key to formulation development. Therefore, this technology is recognized as an exceptionally useful means of improving the dissolution properties of poorly water-soluble drugs and in the latest years, a big deal of understanding has been accumulated about solid dispersion, however, their commercial application is limited. In this review article, emphasis is placed on solubility, BCS classification, and carriers. Moreover, this article presents the diverse preparation techniques for solid dispersion and gathers some of the recent technological transfers. The different types of solid dispersions based on the carrier used and molecular arrangement were underlined. Additionally, it summarizes the mechanisms, the methods of preparing solid dispersions, and the marketed drugs that are available using solid dispersion approaches.
Collapse
|
8
|
Barberis ME, Palma SD, Gonzo EE, Bermúdez JM, Lorier M, Ibarra M, Real JP. Mathematical and Pharmacokinetic Approaches for the Design of New 3D Printing Inks Using Ricobendazole. Pharm Res 2022; 39:2277-2290. [DOI: 10.1007/s11095-022-03320-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 06/19/2022] [Indexed: 10/17/2022]
|
9
|
Arrua EC, Hartwig O, Loretz B, Goicoechea H, Murgia X, Lehr CM, Salomon CJ. Improving the oral delivery of benznidazole nanoparticles by optimizing the formulation parameters through a design of experiment and optimization strategy. Colloids Surf B Biointerfaces 2022; 217:112678. [PMID: 35816885 DOI: 10.1016/j.colsurfb.2022.112678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/30/2022] [Accepted: 06/28/2022] [Indexed: 10/17/2022]
Abstract
Chagas disease is a neglected tropical disease affecting the American continent and also some regions of Europe. Benznidazole, approved by FDA, is a drug of choice but its poor aqueous solubility may lead to a low bioavailability and efficacy. Therefore, the aim of this study was to formulate nanoparticles of benznidazole for improving its solubility, dissolution and permeability. A Plackett-Burman design was applied to identify the effect of 5 factors over 4 responses. Then, a Central Composite design was applied to estimate the values of the most important factors leading to the best compromise between highest nanoprecipitation efficiency, drug solubility and lower particle size. The optimized nanoparticles were evaluated for in vitro drug release in biorelevant media, stability studies and transmission electron microscopy. Biocompatibility and permeability of nanoparticles were evaluated on the Caco-2 cell line. The findings of the optimization process indicated that concentration of drug and stabilizer influenced significantly the particle size while concentration of stabilizer and organic/water phase volume ratio mainly influenced the drug solubility. Stability studies suggested that benznidazole nanoparticles were stable after 12 months at different temperatures. Minimal interactions of those nanoparticles and mucin glycoproteins suggested favorable properties to address the intestinal mucus barrier. Cell viability studies confirmed the safety profile of the optimized formulation and showed an increased permeation through the Caco-2 cells. Thus, this study confirmed the suitability of the design of experiment and optimization approach to elucidate critical parameters influencing the quality of benznidazole nanoparticles, which could lead to a more efficient management of Chagas disease by oral route.
Collapse
Affiliation(s)
- Eva C Arrua
- Instituto de Química de Rosario, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Suipacha 570, 2000 Rosario, Argentina
| | - Olga Hartwig
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbrücken, Germany
| | - Brigitta Loretz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbrücken, Germany
| | - Héctor Goicoechea
- Laboratorio de Desarrollo Analítico y Quimiometría (LADAQ), Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Ciudad Universitaria, 3000 Santa Fe, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Godoy Cruz 2290, C1425FQB Buenos Aires, Argentina
| | - Xabier Murgia
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbrücken, Germany
| | - Claus-Michael Lehr
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbrücken, Germany; Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany
| | - Claudio J Salomon
- Instituto de Química de Rosario, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Suipacha 570, 2000 Rosario, Argentina; Departamento de Farmacia, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 2000 Rosario, Argentina.
| |
Collapse
|
10
|
Nondestructive Investigation of the Agglomeration Process for Nanosuspensions via NMR Relaxation of Water Molecules. Eur J Pharm Sci 2021; 164:105908. [PMID: 34118410 DOI: 10.1016/j.ejps.2021.105908] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 02/24/2021] [Accepted: 06/07/2021] [Indexed: 12/26/2022]
Abstract
This study investigated an agglomeration of nanoparticles in a suspension using nuclear magnetic resonance (NMR) relaxation. The nanosuspension was prepared by wet bead milling using indomethacin and polyvinylpyrrolidone as an active pharmaceutical ingredient (API) and stabilizer, respectively. Transmission profiles using a dispersion analyzer based on multilight scattering technology confirmed that agglomeration occurred at 25 °C immediately after wet bead milling. In this study, we focused on the water molecules, not nanoparticles, and obtained the T2 relaxation time (T2) of the water molecules using the time-domain NMR (TD-NMR) technique. During the storage period, the T2 value rapidly increased at the beginning of the storage. In a suspension system, because the T2 value of water molecules is known to reflect the surface area of the particle, the observed rapid increase in T2 value indicated an agglomeration of nanoparticles. Therefore, it was shown that the measurement of T2 relaxation of a nanosuspension could evaluate the agglomeration process. This technique directly observes water molecules as opposed to nanoparticles. Thus, we believe that TD-NMR is a general-purpose technique that is independent of the type of API or polymer.
Collapse
|
11
|
Dissolution profiles of fenbendazole from binary solid dispersions: a mathematical approach. Ther Deliv 2021; 12:597-610. [PMID: 34286600 DOI: 10.4155/tde-2021-0014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Aim: Understanding a drug dissolution process from solid dispersions (SD) to develop formulations with predictable in vivo performance. Materials & methods: Dissolution data of fenbendazole released from the SDs and the control physical mixtures were analyzed using the Lumped mathematical model to estimate the parameters of pharmaceutical relevance. Results: The fit data obtained by Lumped model showed that all SDs have a unique dissolution profile with an error of ±4.1% and an initial release rate 500-times higher than the pure drug, without incidence of drug/polymer ratio or polymer type. Conclusion: The Lumped model helped to understand that the main factor influencing the fenbendazole release was the type formulation (SD or physical mixture), regardless of the type or amount of polymer used.
Collapse
|
12
|
Özdoğan A, Akca G, Şenel S. Development and in vitro evaluation of gel formulation of atorvastatin solid dispersions. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2020.102199] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Sustained-release hydrogels of ivermectin as alternative systems to improve the treatment of cutaneous leishmaniasis. Ther Deliv 2020; 11:779-790. [PMID: 33198601 DOI: 10.4155/tde-2020-0090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: Leishmaniasis is a neglected tropical disease and its cutaneous form manifests as ulcers or nodules, generally in exposed parts of the body. This work aimed to develop ivermectin (IVM) thermosensitive hydrogels as topical formulations to improve cutaneous leishmaniasis treatment. Materials & methods: Hydrogels based on poloxamers 407 and 188 with different concentrations of IVM were prepared and rheologically characterized. The IVM release profiles were obtained and mathematically analyzed using the Lumped model. Results: The formulation containing 1.5% w/w of IVM presented an adequate gelling temperature, an optimal complex viscosity and elastic modulus. Hydrogels allowed to modulate the release of IVM. Conclusion: IVM thermosensitive hydrogels can be considered a valuable alternative to improve the treatment of cutaneous leishmaniasis.
Collapse
|
14
|
Davies C, Simonazzi A, Micheloud JF, Ragone PG, Cid AG, Negrette OS, Bermúdez JM, Parada LA. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection. J Parasitol 2020; 106:323-333. [PMID: 32369594 DOI: 10.1645/19-80] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Benznidazole and nifurtimox are the only drugs specifically approved for the treatment of Chagas disease. Both compounds are given orally in tablets, but occasionally are ineffective and cause adverse effects. Benznidazole, the first-line treatment in many countries, is a compound with low solubility in water that is administered at high doses for long periods of time. To improve its solubility, we developed a new liquid formulation on the basis of solid dispersions (SD) using the amphiphilic polymer poloxamer 407. Herein we present data on its trypanocidal performance in mouse models of acute and chronic Trypanosoma cruzi infection. SD at doses of 60 or 15 mg/kg per day given with different administration schedules were compared with the commercial formulation (CF; 50 mg/kg per day) and vehicle. The SD performance was assessed by direct parasitemia, total anti-T. cruzi antibodies, and parasitic burden in tissues after 4 or 6 mo posttreatment. The efficacy of the SD was equivalent to the CF but without manifest side effects and hepatotoxicity. Considering our previous data on solubility, together with these on efficacy, this new liquid formulation represents a promising alternative for the treatment of Chagas disease, particularly in cases when dosing poses a challenge, as in infants.
Collapse
Affiliation(s)
- Carolina Davies
- Instituto de Patología Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| | - Analía Simonazzi
- Instituto de Investigaciones para la Industria Química, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| | - Juan Francisco Micheloud
- Grupo de Trabajo de Patología, Epidemiología e Investigación Diagnóstica, Área de Sanidad Animal-IIACS Leales/INTA-Salta, RN 68, km 172, Cerrillos, Salta, Argentina
| | - Paula Gabriela Ragone
- Instituto de Patología Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| | - Alicia Graciela Cid
- Instituto de Investigaciones para la Industria Química, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| | - Olga Sánchez Negrette
- Cátedra de Inmunología, Facultad de Ciencias Agrarias y Veterinarias, Universidad Católica de Salta. Castañares, 4400, Salta, Argentina
| | - José María Bermúdez
- Instituto de Investigaciones para la Industria Química, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| | - Luis Antonio Parada
- Instituto de Patología Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina
| |
Collapse
|
15
|
Therapeutic Applications of Solid Dispersions for Drugs and New Molecules: In Vitro and In Vivo Activities. Pharmaceutics 2020; 12:pharmaceutics12100933. [PMID: 33007806 PMCID: PMC7601702 DOI: 10.3390/pharmaceutics12100933] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 09/27/2020] [Accepted: 09/27/2020] [Indexed: 12/22/2022] Open
Abstract
This review aims to provide an overview of studies that address the use, in therapeutic applications, of solid dispersions (SDs) with biological activities in vitro and/or in vivo mainly made up of polymeric matrices, as well as to evaluate the bioactive activity of their constituents. This bibliographic survey shows that the development of solid dispersions provides benefits in the physicochemical properties of bioactive compounds, which lead to an increase in their biological potential. However, despite the reports found on solid dispersions, there is still a need for biological assay-based studies, mainly in vivo, to assist in the investigation and to devise new applications. Therefore, studies based on such an approach are of great importance to enhance and extend the use of solid dispersions in the most diverse therapeutic applications.
Collapse
|
16
|
Evaluation of the Drug Release Kinetics in Assembled Modular Systems Based on the Dome Matrix Technology. J Pharm Sci 2020; 109:2819-2826. [DOI: 10.1016/j.xphs.2020.06.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 06/04/2020] [Accepted: 06/05/2020] [Indexed: 11/21/2022]
|
17
|
Cid AG, Ramírez-Rigo MV, Palena MC, Gonzo EE, Jimenez-Kairuz AF, Bermúdez JM. Dual Release Model to Evaluate Dissolution Profiles from Swellable Drug Polyelectrolyte Matrices. Curr Drug Deliv 2020; 17:511-522. [DOI: 10.2174/1567201817666200512093115] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 11/25/2019] [Accepted: 03/31/2020] [Indexed: 11/22/2022]
Abstract
Background:
Mathematical modeling in modified drug release is an important tool that allows
predicting the release rate of drugs in their surrounding environment and elucidates the transport
mechanisms involved in the process.
Objective:
The aim of this work was to develop a mathematical model that allows evaluating the release
profile of drugs from polymeric carriers in which the swelling phenomenon is present.
Methods:
Swellable matrices based on ionic complexes of alginic acid or carboxymethylcellulose with
ciprofloxacin were prepared and the effect of adding the polymer sodium salt on the swelling process
and the drug release was evaluated. Experimental data from the ciprofloxacin release profiles were
mathematically adjusted, considering the mechanisms involved in each stage of the release process.
Results:
A proposed model, named “Dual Release” model, was able to properly fit the experimental
data of matrices presenting the swelling phenomenon, characterized by an inflection point in their release
profile. This entails applying the extended model of Korsmeyer-Peppas to estimate the percentage
of drug released from the first experimental point up to the inflection point and then a model called
Lumped until the final time, allowing to adequately represent the complete range of the drug release
profile. Different parameters of pharmaceutical relevance were calculated using the proposed model to
compare the profiles of the studied matrices.
Conclusion:
The “Dual Release” model proposed in this article can be used to predict the behavior of
complex systems in which different mechanisms are involved in the release process.
Collapse
Affiliation(s)
- Alicia Graciela Cid
- Instituto de Investigaciones para la Industria Quimica, Consejo Nacional de Investigaciones Científicas y Tecnicas - Universidad Nacional de Salta, Salta, Argentina
| | | | - María Celeste Palena
- Departamento de Ciencias Farmaceuticas, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, Argentina
| | - Elio Emilio Gonzo
- Instituto de Investigaciones para la Industria Quimica, Consejo Nacional de Investigaciones Científicas y Tecnicas - Universidad Nacional de Salta, Salta, Argentina
| | - Alvaro Federico Jimenez-Kairuz
- Departamento de Ciencias Farmaceuticas, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, Argentina
| | - José María Bermúdez
- Instituto de Investigaciones para la Industria Quimica, Consejo Nacional de Investigaciones Científicas y Tecnicas - Universidad Nacional de Salta, Salta, Argentina
| |
Collapse
|
18
|
Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides. J Control Release 2020; 324:728-749. [PMID: 32380201 DOI: 10.1016/j.jconrel.2020.05.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 05/01/2020] [Accepted: 05/02/2020] [Indexed: 02/06/2023]
Abstract
Antibiotic resistance has become a global crisis, driving the exploration for novel antibiotics and novel treatment approaches. Among these research efforts two classes of antibiotics, bicyclic nitroimidazoles and antimicrobial peptides, have recently shown promise as novel antimicrobial agents with the possibility to treat multi-drug resistant infections. However, they suffer from the issue of poor oral bioavailability due to disparate factors: low solubility in the case of nitroimidazoles (BCS class II drugs), and low permeability in the case of peptides (BCS class III drugs). Moreover, antimicrobial peptides present another challenge as they are susceptible to chemical and enzymatic degradation, which can present an additional pharmacokinetic hurdle for their oral bioavailability. Formulation technologies offer a potential means for improving the oral bioavailability of poorly permeable and poorly soluble drugs, but there are still drawbacks and limitations associated with this approach. This review discusses in depth the challenges associated with oral delivery of nitroimidazoles and antimicrobial peptides and the formulation technologies that have been used to overcome these problems, including an assessment of the drawbacks and limitations associated with the technologies that have been applied. Furthermore, the potential for supercritical fluid technology to overcome the shortcomings associated with conventional drug formulation methods is reviewed.
Collapse
|
19
|
Barrera MG, Tejada G, Leonardi D, Lamas MC, Salomón CJ. A Novel Prototype Device for Microencapsulation of Benznidazole: In Vitro/In Vivo Studies. AAPS PharmSciTech 2020; 21:112. [PMID: 32236813 DOI: 10.1208/s12249-020-01659-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 03/13/2020] [Indexed: 12/30/2022] Open
Abstract
This study was aimed to design a simple and novel prototype device for the production of polymeric microparticles. To prove the effectiveness of this device, benznidazole microparticles using chitosan as carrier and NaOH, KOH, or SLS as counter ions were used. For comparison, benznidazole microparticles were prepared by the conventional dripping technique (syringe and gauge) using the same excipients. Microparticles were characterized in terms of encapsulation efficiency, particle shape, size and surface topography, crystallinity characteristics, thermal behavior, and dissolution rate. Then, the pharmacokinetic parameters were evaluated after the oral administration of the microparticles to healthy Wistar rats. The prepared formulations, by means of this device, showed good drug encapsulation efficiency (> 70%). Release studies revealed an increased dissolution of benznidazole from chitosan microparticles prepared using the novel device. It achieved more than 90% in 60 min, while those of the conventional microparticles and raw drug achieved 65% and 68%, respectively, during the same period. Almost spherical benznidazole microparticles with a smooth surface and size around 10-30 μm were observed using scanning electron microscopy. Thermal analysis and X-ray diffraction studies suggested a partial reduction of drug crystallinity. Moreover, the relative oral bioavailability of the novel benznidazole microparticles showed that the area under the curve for the microencapsulated drug was 10.3 times higher than the raw drug. Thus, these findings indicate that the designed glass prototype device is a useful alternative to formulate benznidazole polymeric microparticles with improved biopharmaceutical properties and could be useful for other therapeutic microparticulate systems.
Collapse
|
20
|
Benznidazole self-emulsifying delivery system: A novel alternative dosage form for Chagas disease treatment. Eur J Pharm Sci 2020; 145:105234. [PMID: 31978590 DOI: 10.1016/j.ejps.2020.105234] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 01/09/2020] [Accepted: 01/21/2020] [Indexed: 12/14/2022]
Abstract
Benznidazole (BZ) tablets are a unique form of treatment available for treating Chagas disease. Development of a liquid formulation containing BZ easy to administer orally for the treatment of paediatric patients, particularly for newborns is urgently required, with the same efficacy, safety and suitable biopharmaceutical properties as BZ tablets. Self-emulsifying drug delivery systems (SEDDS) may improve bioavailability of drugs such as BZ, which have poor water solubility and low permeability. In this context, the aim of this work was to develop a liquid BZ-SEDDS formulation as an alternative to tablets and to evaluate its cytotoxicity in different host cell lines and its efficacy in experimental Trypanosoma cruzi infection in mice. The optimized SEDDS formulation (25 mg/ml of BZ) induced no cytotoxicity in H9c2, HepG2 and Caco2 cells in vitro at 25 μM level. BZ-SEDDS and free-BZ showed similar in vitro trypanocidal activity in H9c2 cells infected by T. cruzi Y strain, with IC50 values of 2.10 ± 0.41 μM and 1.29 ± 0.01 μM for BZ and BZ-SEDDS, respectively. A follow up of efficacy in an acute model of infected mice resulted in the same percentage of cure (57%) for both free-BZ and BZ-SEDDS- groups according to established parameters. Furthermore, no additional in vivo toxicity was observed in animals treated with BZ-SEDDS. Taken together, in vitro and in vivo data of BZ-SEDDS showed that the incorporation of BZ into SEDDS does not alter its potency, efficacy and safety. Thus, BZ-SEDDS can be a more practical and personalized orally administered liquid dosage form compared to suspension of crushed BZ-tablets to treat newborn and young children by emulsifying SEDDS in different aqueous liquids with advantage of dosing flexibility.
Collapse
|
21
|
Tran PH, Duan W, Lee BJ, Tran TT. Modulation of Drug Crystallization and Molecular Interactions by Additives in Solid Dispersions for Improving Drug Bioavailability. Curr Pharm Des 2019; 25:2099-2107. [DOI: 10.2174/1381612825666190618102717] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 05/24/2019] [Indexed: 11/22/2022]
Abstract
Background::
An increase in poorly water-soluble drugs makes the design of drug delivery systems
challenging.
Methods::
Currently, a number of prospective solid dispersions have been investigated with potential applications
for delivering a variety of poorly water-soluble drugs. A number of traditional solid dispersions and modifiedsolid
dispersions offer attractive advantages in the fabrication, design and development of those drugs for effective
therapeutics.
Results::
Although traditional solid dispersions can produce a higher release rate, resulting in higher bioavailability
compared to conventional dosage forms, this method is not always a promising approach. Modified-solid
dispersion has demonstrated both the ability of its polymers to transform drug crystals into amorphous forms and
molecular interactivity, thereby improving drug dissolution rate and bioavailability, especially with tough drugs.
However, the classification of modified-solid dispersion, which guides the selection of the right strategy in solid
dispersion preparation, remains ill-defined.
Conclusions::
This review focused on effective strategies in using additives in solid dispersion for improving drug
bioavailability.
Collapse
Affiliation(s)
| | - Wei Duan
- Deakin University, School of Medicine, Geelong, Australia
| | - Beom-Jin Lee
- College of Pharmacy, Ajou University, Suwon, Korea
| | - Thao T.D. Tran
- Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Vietnam
| |
Collapse
|
22
|
Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization. Pharmaceutics 2019; 11:pharmaceutics11050206. [PMID: 31052438 PMCID: PMC6572573 DOI: 10.3390/pharmaceutics11050206] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 04/22/2019] [Accepted: 04/24/2019] [Indexed: 11/17/2022] Open
Abstract
LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the present study aimed to develop ternary solid dispersion (SD) formulations in order to enhance the aqueous solubility and dissolution rate of LW6. Various SDs of LW6 were prepared using a solvent evaporation method with different drug/excipient ratios. The solubility and dissolution profiles of LW6 in different SDs were examined, and F8-SD which is composed of LW6, poloxamer 407, and povidone K30 at a weight ratio of 1:5:8 was selected as the optimal SD. The structural characteristics of F8-SD were also examined using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (SEM). In the acidic to neutral pH range, F8-SD achieved rapid dissolution with a drug release of 76–81% within 20 min, while the dissolution of pure LW6 was negligible. The XRPD patterns indicated that F8-SD probably enhanced the solubility and dissolution of LW6 by changing the drug crystallinity to an amorphous state, in addition to the solubilizing effect of the hydrophilic carriers. Furthermore, F8-SD significantly improved the oral bioavailability of topotecan, which is a BCRP substrate, in rats. The systemic exposure of topotecan was enhanced approximately 10-fold by the concurrent use of F8-SD. In conclusion, the ternary SD formulation of LW6 with povidone K30 and poloxamer 407 appeared to be effective at improving the dissolution and in vivo effects of LW6 as a BCRP inhibitor.
Collapse
|
23
|
Villegas M, Cid AG, Briones CA, Romero AI, Pistán FA, Gonzo EE, Gottifredi JC, Bermúdez JM. Films based on the biopolymer poly(3-hydroxybutyrate) as platforms for the controlled release of dexamethasone. Saudi Pharm J 2019; 27:694-701. [PMID: 31297024 PMCID: PMC6598214 DOI: 10.1016/j.jsps.2019.04.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 04/01/2019] [Indexed: 11/18/2022] Open
Abstract
Controlled drug delivery aims to achieve an effective drug concentration in the action site for a desired period of time, while minimizing side effects. In this contribution, biodegradable poly(3-hydroxybutyrate) films were evaluated as a reservoir platform for dexamethasone controlled release. These systems were morphological and physicochemically characterized. In vitro release assays were performed for five different percentages of drug in the films and data were fitted by a mathematical model developed and validated by our research group. When the profiles were normalized, a single curve properly fitted all the experimental data. Using this unique curve, the dissolution efficiency (DE), the time to release a given amount of drug (tX% ), and the mean dissolution time were calculated. Furthermore, the dissolution rate, the initial dissolution rate (a%) and the intrinsic dissolution rate were determined. The a% mean value was 1.968 × 10-2% released/min, t80% was about 14 days, and the DE was 59.6% at 14 days and 66.5% at 20 days. After 2 days, when approximately 40% of the drug was released, the dissolution rate decreased about 60% respect to the initial value. The poly(3-hydroxybutyrate) platforms behaved as an appropriate system to release and control the dexamethasone delivery, suggesting that they could be an alternative to improve drug therapy.
Collapse
Affiliation(s)
- Mercedes Villegas
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Alicia Graciela Cid
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Cintia Alejandra Briones
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Analía Irma Romero
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Florencia Alejandra Pistán
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Elio Emilio Gonzo
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - Juan Carlos Gottifredi
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
| | - José María Bermúdez
- Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Facultad de Ingeniería, Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital 4400, Argentina
- Corresponding author at: Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta – Consejo Nacional de Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital 4400, Argentina.
| |
Collapse
|
24
|
Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts. J Mol Cell Cardiol 2019; 128:134-144. [DOI: 10.1016/j.yjmcc.2019.01.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2018] [Revised: 01/02/2019] [Accepted: 01/31/2019] [Indexed: 01/01/2023]
|
25
|
Colombo M, de Lima Melchiades G, Michels LR, Figueiró F, Bassani VL, Teixeira HF, Koester LS. Solid Dispersion of Kaempferol: Formulation Development, Characterization, and Oral Bioavailability Assessment. AAPS PharmSciTech 2019; 20:106. [PMID: 30746582 DOI: 10.1208/s12249-019-1318-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 01/22/2019] [Indexed: 02/06/2023] Open
Abstract
Kaempferol (KPF), an important flavonoid, has been reported to exert antioxidant, anti-inflammatory, and anticancer activity. However, this compound has low water solubility and hence poor oral bioavailability. This work aims to prepare a solid dispersion (SD) of KPF using Poloxamer 407 in order to improve the water solubility, dissolution rate, and pharmacokinetic properties KPF. After optimization, SDs were prepared at a 1:5 weight ratio of KPF:carrier using the solvent method (SDSM) and melting method (SDMM). Formulations were characterized by Fourier transform infrared spectroscopy (FTIR), X-ray diffractometry (XRD) analysis, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). The solubility in water of carried-KPF was about 4000-fold greater than that of free KPF. Compared with free KPF or the physical mixture, solid dispersions significantly increased the extent of drug release (approximately 100% within 120 min) and the dissolution rate. Furthermore, after oral administration of SDMM in rats, the area under the curve (AUC) and the peak plasma concentration (Cmax) of KPF from SDMM were twofold greater than those of free KPF (p < 0.05). In conclusion, SD with Poloxamer 407 is a feasible pharmacotechnical strategy to ameliorate the dissolution and bioavailability of KPF.
Collapse
|